Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
abducens nerve paralysis
acetylcholine receptor antibody
acoustic nerve
advances in neurology
adverse drug reaction
afebrile
agitation
anti GQ1b IgG antibody
antiviral agents
aphasia
areflexia
arteritides
arteritis, temporal
arteritis, temporal, recurrent
arthralgia
ataxia, sensory
atezolizumab
atypical
autoantibodies
autoimmune disease
autonomic dysfunction
B cell lymphoma
brain biopsy
Broca's aphasia
burning paresthesia
cancer associated myopathy
carcinoma
carcinoma of lung
cardiotoxicity
CAT scan, emission, abnormal
cauda equina
cauda equina, enhancement
cauda equina, lesion of
CD19-directed chimeric antigen receptor T-cell therapy
cerebellitis
cerebellitis, autoimmune
cerebral arteries
cerebrovascular accident
chemotherapy, CNS treatment and complications with
chorea
coinfection
complications
confusion
confusional state, acute
cranial nerve palsies
cranial neuropathy
cranial neuropathy, multiple
creatine phosphokinase(CPK)elevated
cytokine release syndrome
dabrafenib
demyelinating disease
dentate nuclei
dentate nuclei, lesion of
diabetes insipidus
differential diagnosis
diplopia
disorientation
dropped head syndrome
drug abuse
drug induced neurologic disorders
duvalumab
dyspnea
efficacy
electroencephalogram, abnormalities of
electromyogram
encephalitis
encephalitis, autoimmune
encephalitis, viral
encephalopathy
encephalopathy, acute
episodic disorders
extralimbic encephalitis
face, numbness of
facial nerve palsy
fever
Fisher's syndrome
gammaglobulin therapy, intravenous
ganglionitis
glutamic acid decarboxylase, antibody
granulomatous hypophysitis
Guillain Barre syndrome
hallucination
hallucination, auditory
hallucination, visual
headache
hemiparesis
hemiplegia, progressive
hippocampal atrophy
hippocampus, hyperintense
Hodgkin's disease
human herpesvirus 6
hyperactivity
hypercalcemia
iatrogenic neurologic disorders
idiopathic
immune checkpoint inhibitors
immune effector cell-associated neurotoxicity syndrome
immune-related adverse events
immunologic disease
immunomodulation
immunosuppression
immunosuppressive agents
immunotherapy
incidence
internal carotid artery
ipilimumab
JC virus
leukopenia
levamisole
limb-girdle weakness
limbic encephalitis
limbic system
lymph node biopsy
lymphadenopathy
lymphoma
lymphoma, systemic
melanoma, malignant
memory, impairment of
meningismus
meningitis
meningitis, drug induced
meningoencephalitis
mental status, abnormal
mesial temporal lobe
middle cerebral artery
misdiagnosis
monoclonal antibodies
mortality
MRI, abnormal
MRI, angiography
MRI, contrast enhanced
MRI, diffusion weighted
MRI, FLAIR
MRI, optic nerve
multiple organ failure
multiple sclerosis
muscle biopsy
muscle pain
muscle weakness
muscle weakness, proximal
myasthenia gravis
myasthenia gravis, drug induced
myasthenia gravis, unmasked
myocarditis
myopathy
myopathy, inflammatory
myopathy, necrotizing
myopathy, necrotizing, immune-mediated
myositis
nausea and vomiting
neck weakness
neoplasm, metastatic
neoplasm, metastatic to CNS
neoplasm, metastatic to CNS-treatment of
neurologic complications of, systemic cancer
neurologic complications of, systemic disease
neurologic disease
neurologic disease, diagnoses of
neurologic disease, multiple
neuromuscular junction
neuromuscular junction, abnormality of
neuronopathy, sensory
neuroophthalmology
neuropathy
neuropathy, iatrogenic
neuropathy, medication induced
neuropathy, sensory
neurotoxic
nivolumab
ocular motility, disorders of
ophthalmoplegia
opportunistic infection
opportunistic infection, CNS
optic disc edema
optic nerve, enhancement
optic neuritis
optic neuropathy
orthostatic hypotension
paraneoplastic ganglionopathy
paresthesias
pembrolizumab
pituitary stalk
pituitary stalk, enlarged
plasmapheresis
pleocytosis of cerebrospinal fluid
polymerase chain reaction, false negative
polyneuropathy, chronic inflammatory demyelinating
precipitating factors
prognosis
progressive multifocal leucoencephalopathy
progressive neurologic disorder
pruritus
pseudoathetosis
ptosis
ptosis, bilateral
radiation therapy, CNS treatment and complications with
rechallenge
recurrent
remote effect of cancer on the nervous system
respiratory failure
review article
rhabdomyolysis
risk factors
Romberg's sign
safety
sarcoidosis
sarcoidosis, CNS
seizure
sensory ganglia
sensory ganglia, abnormal
sensory loss
sensory loss, truncal
seronegative
Sjogren's syndrome
speech disorder
speech, slowed
steroid
steroid therapy, CNS treatment and complications with
systemic illness
temporal lobe, lesion
temporal lobe, lesion, bilateral
trametinib
treatment of neurologic disorder
tumor necrosis factor inhibitor
vasculitides
viral infection, CNS
visual acuity, decreased
visual loss
weakness
weakness, fatiguable
white matter disease
word-finding difficulty
workup
Showing articles 750 to 800 of 2210 << Previous Next >>

Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007

How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007

Stroke in Patients with Human Immunodeficiency Virus Infection
JNNP 78:1320-1324,1291, Tipping,B.,et al, 2007

Limbic Encephalitis: Under-Recognition of Voltage-Gated Potassium Channel Antibodies
Eur Neurol 58:184, Irani,S.R., et al, 2007

Course and Outcome of Acute Limbic Encephalitis With Negative Voltage-Gated Potassium Channel Antibodies
JNNP 78:391-394, Samarasekera,S.R., et al, 2007

Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis
Mod Rheumatol 17-72-74, Yamamoto, M.,et al, 2007

Inclusion Body Mositis With Human Immunodeficiency Virus Infection: Four Cases with Clonal Expansion of Viral-Specific T Cells
Ann Neurol 61:466-475, Dalakas,M.,et al, 2007

MRI Outcomes in a Placebo-Controlled Trial of Natalizumab in Relapsing MS
Neurol 68:1390-1401, Miller,D.H.,et al, 2007

Refractory Neurosarcoidosis Responsive to Infliximab
Pract Neurol 7:112-115, Kobylecki,C. &Shaunak,S., 2007

Multiple Ring Enhancing Lesions in Brain MRI of a Patient with AIDS
JNNP 78:526, Tahir,M.,et al, 2007

Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007

Neurological Findings in Aminoacylase 1 Deficiency
Neurol 68:2151-2153, Sass,J.O.,et al, 2007

Post-Transplant Acute Limbic Encephalitis: Clinical Features and Relationship to HHV6
Neurol 69:156-165, Seeley,W.W.,et al, 2007

Inflammatory Progressive Multifocal Leukoencephalopathy in Human Immunodeficiency Virus-Negative Patients
Ann Neurol 62:34-39, Huang,D.R.,et al, 2007

Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007

Progressive Multifocal Leukoencephalopathy After Rituximab in a Case of Non-Hodgkin Lymphoma
Neurol 69:704-706, Kranick,S.M.,et al, 2007

Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007

Limbic Encephalitis as a Precipitating Event in Adult-Onset Temporal Lobe Epilepsy
Neurol 69:1236-1244, Bien,C.G.,et al, 2007

Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment
Neurologist 13:261-271, Tuzun,E. &Dalmau,J., 2007

Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007

Mysterious Falls and a Nasal Voice
Lancet 370:712, Bhandari,A. &Adenwalla,F., 2007

Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007

The Incidence and Significance of Anti-Natalizumab Antibodies: Results from AFFIRM and SENTINEL
Neurol 69:1391-1403,1396, Calabresi,P.A.,et al, 2007

Assessment of Declofenac or Spinal Manipulative Therapy, Or Both, in Addition to Recommended First-Line Treatment for Acute Low Back Pain: A Randomised Controlled Trial
Lancet 370:1638-1643, Hancock,M.J., et al, 2007

Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007

Antiedema Therapy in Ischemic Stroke
Stroke 38:3084-3094, Bardutzky,J. &Schwab,S., 2007

Continuous Spectrum of Pharyngeal-Cervical-Brachial Variant of Guillain-Barr� Syndrome
Arch Neurol 64:1519-1523, Nagashima,T.,et al, 2007

Clinicopath Conf., Paraneoplastic Cerebellar Degeneration Due to Anti-Yo Antibodies From Breast Cancer
NEJM 356:612-620, Case 4-2007, 2007

Paraneoplastic Anti-N-methyl-D-aspartate Receptor Encephalitis Associated With Ovarian Teratoma
Ann Neurol 61:25-36,3, Dalmau,J.,et al, 2007

Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007

Optic Pathway Gliomas in Neurofibromatosis-1: Controversies and Recommendations
Ann Neurol 61:189-198, Listernick,R.,et al, 2007

Randomized, Double-Blind, Dose-Comparison Study of Glatiramer Acetate in Relapsing-Remitting MS
Neurol 68:939-944, Cohen,J.A.,et a, 2007

Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007

Intravenous Immunoglobulin Therapy for Miller Fisher Syndrome
Neurol 68:1144-1146, Mori,M.,et al, 2007

Autoimmune Limbic Encephalitis in 39 Patients: Immunophenotypes and Outcomes
JNNP 78:381-385,332, Bataller,L.,et al, 2007

Sumatriptan-Naproxen for Acute Treatment of Migraine, A Randomized Trial
JAMA 297:1443-1454, Brandes,J.L.,et al, 2007

Natalizumab Reduces Visual Loss in Patients with Relapsing Multiple Sclerosis
Neurol 68:1299-1302, Balcer,L.J.,et al, 2007

Immune Reconstitution Inflammatory Syndrome Associated with PML in AIDS: A Treatable Disorder
Neurol 67:1692-1694, Martinez,J.V.,et al, 2006

Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006

Infusion-Related Hypersensitivity Reactions During Natalizumab Treatment
Neurol 67:1717-1718, Phillips,J.T.,et al, 2006

Charcot Neuroarthropathy in the Era of HAART
Lancet 367:274, Oh-Park,M.,et al, 2006

Recent Advances in the Diagnosis and Management of Migraine
BMJ 332:25-29, Goadsby,P.J., 2006

Chronic Daily Headache
NEJM 354:158-165, Dodick,D.W., 2006

A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006

Paraneoplastic Encephalomyelitis Associated with Pancreatic Tumor and anti-GAD Antibodies
Neurol 66:450-451, Hernandez-Echebarria,L.,et al, 2006

Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006

Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
NEJM 354:924-933,965, Yousry,T.A.,et al, 2006

IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006

Clinicopath Conf, Diffuse Large B-Cell Lymphoma, EBV-Positive, with Immunosuppression
NEJM 354:1178-1184, Case 8-2006, 2006



Showing articles 750 to 800 of 2210 << Previous Next >>